Search Results - Craig T. Wallington‐Beddoe
- Showing 1 - 11 results of 11
-
1
-
2
-
3
-
4
-
5
-
6
Expression of the chemokine receptor CCR1 decreases sensitivity to bortezomib in multiple myeloma cell lines by Mara N. Zeissig, D. Hewett, Krzysztof M. Mrozik, Vasilios Panagopoulos, Craig T. Wallington‐Beddoe, Andrew Spencer, Sandra Maria Dold, Monika Engelhardt, Kate Vandyke, Andrew C.W. Zannettino
Published 2024Artigo -
7
Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress by Craig T. Wallington‐Beddoe, Melissa K. Bennett, Kate Vandyke, Lorena T. Davies, Julia R. Zebol, Paul A.B. Moretti, Melissa R. Pitman, D. Hewett, Andrew C.W. Zannettino, Stuart M. Pitson
Published 2017Artigo -
8
Daratumumab, cyclophosphamide, bortezomib and dexamethasone for non-transplant eligible myeloma (AMaRC 03-16) by Peter Mollee, John Reynolds, Wojt Janowski, Hang Quach, Philip Campbell, Simon Gibbs, Sophie Lee, Edwin Lee, Kerry Taylor, Tara Cochrane, Craig T. Wallington‐Beddoe, Fiona Kwok, N Weber, Ian Kerridge, Helen Weston, P. Joy Ho, Michael F. Leahy, Noemi Horvath, Andrew Spencer
Published 2024Artigo -
9
Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia by Jason A. Powell, Alexander C. Lewis, Wenying Zhu, John Toubia, Melissa R. Pitman, Craig T. Wallington‐Beddoe, Paul A.B. Moretti, Diana Iarossi, Saumya E. Samaraweera, Nik Cummings, Hayley S. Ramshaw, Danièl Thomas, Andrew H. Wei, Angel F. López, Richard J. D’Andrea, Ian D. Lewis, Stuart M. Pitson
Published 2016Artigo -
10
Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia by Alexander C. Lewis, Victoria S. Pope, Melinda N. Tea, Manjun Li, Gus O. Nwosu, Thao M. Nguyen, Craig T. Wallington‐Beddoe, Paul A.B. Moretti, Dovile Anderson, Darren J. Creek, Maurizio Costabile, Saira R. Ali, Chloe Thompson-Peach, B. Kate Dredge, Andrew G. Bert, Gregory J. Goodall, Paul G. Ekert, Anna Brown, Richard J. D’Andrea, Nirmal Robinson, Melissa R. Pitman, Danièl Thomas, David M. Ross, Briony L. Gliddon, Jason A. Powell, Stuart M. Pitson
Published 2022Artigo -
11
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phas... by Sebastian Grosicki, Maryana Simonova, Ivan Špıčka, Luděk Pour, Iryrna Kriachok, Maria Gavriatopoulou, Halyna Pylypenko, Holger W. Auner, Xavier Leleu, Vadim Doronin, Ganna Usenko, Nizar J. Bahlis, Roman Hájek, Reuben Benjamin, Tuphan Kanti Dolai, Dinesh Kumar Sinha, Christopher P. Venner, Mamta Garg, Mercedes Gironella, Artur Jurczyszyn, Paweł Robak, Mónica Galli, Craig T. Wallington‐Beddoe, Atanas Radinoff, Galina Salogub, Don A. Stevens, Supratik Basu, Anna Marina Liberati, Hang Quach, Vesselina Goranova‐Marinova, Jelena Bila, Eirini Katodritou, Hanna Oliynyk, Sybiryna Korenkova, Jeevan Kumar, Sundar Jagannath, Philippe Moreau, Moshe Levy, Darrell White, Moshe E. Gatt, Thierry Façon, María‐Victoria Mateos, Michèle Cavo, Donna Reece, Larry D. Anderson, Jean-Richard Saint-Martin, Jacqueline Jeha, Anita Joshi, Yi Chai, Lingling Li, Vishnuvardhan Peddagali, Melina Arazy, Jatin J. Shah, Sharon Shacham, Michael Kauffman, Meletios Α. Dimopoulos, Paul G. Richardson, Sosana Delimpasi
Published 2020Artigo
Search Tools:
Related Subjects
Biology
Cancer research
Medicine
Internal medicine
Multiple myeloma
Bortezomib
Apoptosis
Biochemistry
Genetics
Oncology
Gene
Immunology
Leukemia
Receptor
Sphingosine
Cancer
Cell biology
Ceramide
Dexamethasone
Myeloid leukemia
Pharmacology
Programmed cell death
Sphingosine kinase 1
Sphingosine-1-phosphate
Autophagy
Bioinformatics
Biomarker
Biomarker discovery
CCR1
Cancer drugs